1. Home
  2. LXFR vs PRTA Comparison

LXFR vs PRTA Comparison

Compare LXFR & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Luxfer Holdings PLC

LXFR

Luxfer Holdings PLC

HOLD

Current Price

$17.10

Market Cap

460.7M

Sector

Industrials

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$8.49

Market Cap

526.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LXFR
PRTA
Founded
1898
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
460.7M
526.7M
IPO Year
2002
2013

Fundamental Metrics

Financial Performance
Metric
LXFR
PRTA
Price
$17.10
$8.49
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$19.00
AVG Volume (30 Days)
389.2K
537.0K
Earning Date
04-28-2026
05-07-2026
Dividend Yield
3.65%
N/A
EPS Growth
N/A
N/A
EPS
0.13
0.60
Revenue
$384,600,000.00
$814,000.00
Revenue This Year
N/A
$1,111.38
Revenue Next Year
$5.01
N/A
P/E Ratio
$131.54
$14.15
Revenue Growth
N/A
N/A
52 Week Low
$11.26
$7.40
52 Week High
$19.45
$11.80

Technical Indicators

Market Signals
Indicator
LXFR
PRTA
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
LXFR
PRTA

About LXFR Luxfer Holdings PLC

Luxfer Holdings PLC is engaged in materials engineering and the manufacture of materials, components, and gas containment products. The company has two reportable segments: Elektron and Gas Cylinders. The Elektron segment produces specialty materials based on magnesium and zirconium for applications in aerospace, defense, automotive, and industrial markets. The Gas Cylinders segment manufactures high-pressure gas containment products using aluminum alloys and carbon composite technologies for use in healthcare, emergency response, aerospace, and alternative fuel transportation markets.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: